

SCIENTIFIC REPORTS



OPEN

Molecular typing and virulence analysis of multidrug resistant *Klebsiella pneumoniae* clinical isolates recovered from Egyptian hospitals

Received: 04 October 2016
Accepted: 15 November 2016
Published: 22 December 2016

Reham Wasfi¹, Walid F. Elkhatib^{2,3} & Hossam M. Ashour^{4,5}

Klebsiella pneumoniae infection rates have increased dramatically. Molecular typing and virulence analysis are powerful tools that can shed light on *Klebsiella pneumoniae* infections. Whereas 77.7% (28/36) of clinical isolates indicated multidrug resistant (MDR) patterns, 50% (18/36) indicated carbapenem resistance. Gene prevalence for the AcrAB efflux pump (82.14%) was more than that of the mdtK efflux pump (32.14%) in the MDR isolates. *FimH-1* and *mrkD* genes were prevalent in wound and blood isolates. *FimH-1* gene was prevalent in sputum while *mrkD* gene was prevalent in urine. Serum resistance associated with outer membrane protein coding gene (*traT*) was found in all blood isolates. *lucC*, *entB*, and *Irp-1* were detected in 32.14%, 78.5% and 10.7% of MDR isolates, respectively. We used two Polymerase Chain Reaction (PCR) analyses: Enterobacterial Repetitive Intergenic Consensus (ERIC) and Random Amplified Polymorphic DNA (RAPD). ERIC-PCR revealed 21 and RAPD-PCR revealed 18 distinct patterns of isolates with similarity $\geq 80\%$. ERIC genotyping significantly correlated with resistance patterns and virulence determinants. RAPD genotyping significantly correlated with resistance patterns but not with virulence determinants. Both RAPD and ERIC genotyping methods had no correlation with the capsule types. These findings can help up better predict MDR *Klebsiella pneumoniae* outbreaks associated with specific genotyping patterns.

K. pneumoniae belongs to family Enterobacteriaceae and is related to other genera, such as *Enterobacter*, *Escherichia*, and *Salmonella*¹. *K. pneumoniae* is considered one of the most common Gram negative bacteria². It is also an important pathogen in nosocomial infections in Egypt^{3,4}. A number of factors contribute to virulence and pathogenicity in *K. pneumoniae* such as the capsular serotype, lipopolysaccharide, iron-scavenging systems and adhesions⁵. Iron acquisition systems are essential for the growth of pathogenic bacteria⁶. Moreover, the iron chelator siderophore allows bacteria to take up protein-bound iron from the host cells⁷.

The incidence of microbial infections has been increasing in the past few decades. This has led to the continuous and uncontrolled use of antimicrobial drugs for prevention and treatment in several parts of the world. This, in turn, led to the emergence of specific drug and multidrug resistance among various strains of microorganisms including *K. pneumoniae*⁸. Gram-negative bacteria have developed several mechanisms of resistance to currently used antimicrobials. One of the successful mechanisms for transmitting multiple-drug resistance among bacterial pathogens is horizontal transfer⁹. The spread of MDR isolates in the clinic has been attributed to commonly shared plasmids across bacteria such as *K. pneumoniae*, *K. oxytoca*, *Escherichia coli*, *Enterobacter sp.*, and *Salmonella sp.*^{10,11}. The efflux pump systems are among the most important causes of MDR¹². Efflux pump systems in *K. pneumoniae* include AcrAB and mdtK systems. These belong to the Resistance Nodulation Division

¹Department of Microbiology & Immunology, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt. ²Department of Microbiology & Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. ³Department of Pharmacy Practice, School of Pharmacy, Chapman University, Orange, California, USA. ⁴Department of Biological Sciences, College of Arts and Sciences, University of South Florida St. Petersburg, St. Petersburg, Florida, USA. ⁵Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Correspondence and requests for materials should be addressed to H.M.A. (email: hossamking@mailcity.com)

(RND) and Multi Antimicrobial Extrusion (MATE) family efflux pumps, respectively. The AcrAB-TolC pump is composed of an outer-membrane channel (TolC), a secondary transporter located in the inner membrane (AcrB), and a periplasmic component (AcrA)¹³. This pump is responsible for resistance to quinolones, tetracyclines, and chloramphenicol in various MDR isolates¹⁴. The MATE pumps, such as the *mdtK* system, transport some of those antimicrobial agents¹⁵. Porins such as *OmpK35* and *OmpK36* are crucial for the penetration of antibiotics into the cells and for susceptibility to cephalosporins and carbapenems¹⁶.

Carbapenems have been used for the treatment of infections caused by Enterobacteriaceae¹⁷. The percentage of Carbapenem-resistant Enterobacteriaceae (CRE) has been on the rise¹⁸. One of the most prominent recent increases of MDR was observed with *Klebsiella sp.* In the period from 2001 through 2011¹⁸. It is noteworthy that patients with infections due to carbapenemase-producing enterobacteriaceae, such as *K. pneumoniae* experience high mortality rates^{19–21}. Normally, these MDR infections are hard-to-treat with limited available choices of antibiotics such as tigecycline, colistin, fosfomycin, and aminoglycosides^{22,23}.

Molecular typing and virulence analysis of clinical isolates are powerful tools that can shed light on multidrug resistant (MDR) *Klebsiella pneumoniae* infections. We also used two Polymerase Chain Reaction (PCR) genotyping analyses: Enterobacterial Repetitive Intergenic Consensus (ERIC) and Random Amplified Polymorphic DNA (RAPD) to assess correlations of each with resistance patterns, virulence determinants, or capsule types of *K. pneumoniae* isolates.

Results

Primers. Primers used for amplification are listed in Table 1. More detail is provided under materials and methods.

Clinical isolates. Thirty six of *K. pneumoniae* clinical isolates were collected as described under materials and methods. Isolates were recovered from specimens of urine (n = 16), wound (n = 4), cerebrospinal fluid CSF (n = 1), blood (n = 7), sputum (n = 8) on MacConkey's agar. Colonies showing lactose fermenting ability were further identified both microscopically and biochemically.

Antimicrobial susceptibility pattern and detection of genes coding for MDR efflux pumps and outer membrane porins.

As determined by disc diffusion antimicrobial susceptibility testing method, a percentage 77.7% (28/36) of isolates showed multidrug resistance (MDR) patterns, but all these MDR isolates were sensitive to colistin (10 µg). All MDR isolates were resistant to beta lactam antibiotics and 64.28%, 82.15%, and 85.7% showed resistance to carbapenem, quinolone, and aminoglycosides, respectively. Tetracycline and chloramphenicol were effective against 61.1% of carbapenem-resistant isolates. The tested isolates were distributed into 24 antimicrobial resistance patterns (Table 2). Most patterns showed resistance to cephalosporin and beta lactam/beta lactamase inhibitors. The most predominant pattern was A6 and A8.

Gene prevalence for the AcrAB efflux pump system (82.14%) was more than that of the *mdtK* efflux pump (32.14%) in the MDR isolates. Incomplete AcrAB efflux pump system was detected in the remaining five isolates. The genes coding for porin protein (*ompK35*) and (*ompK36*) were not detected in six and four MDR isolates, respectively. Genes coding for the porins (*ompK 35* and *ompK36*) were detected in all isolates recovered from wound and CSF specimens. The presence of these two porin-coding genes was variable in blood, sputum, and urine samples.

Detection of virulence genes. The prevalence and distribution of virulence factors are shown in Table 3. The *fimH-1* and *mrkD* genes, encoding type 1 and type 3 fimbrial adhesins, were present in all wound and blood isolates. The *fimH-1* gene was prevalent in sputum isolates whereas *mrkD* gene was prevalent in all urine samples. Serum resistance associated with the outer membrane protein coding gene (*traT*) was detected in all blood isolates.

The iron siderophores, aerobactin synthase gene (*IucC*), enterobactin biosynthesis gene (*entB*) and Yersinibactin biosynthesis gene (*Irp-1*) were detected in 32.14%, 85.7% and 28.5% of MDR isolates, respectively.

The prevalence of capsule K genotypes in the 28 MDR isolates revealed that K1 (n = 8), K2 (n = 2) and the remaining isolates were non-typable as K1 or K2 genotypes. Isolates showing K1 genotypes were obtained from urine, blood, and sputum specimens, while K2 isolates was recovered from urine and wound samples. There were 16 virulence profiles according to detected virulence genes. It is noteworthy that virulence genetic profiles indicated that virulence determinants were variable among *K. pneumoniae* strains that possess the same capsule genotype (Table 3).

Genotyping of *Klebsiella pneumoniae* isolates by RAPD and ERIC analyses.

According to the dendrograms, Enterobacterial Repetitive Intergenic Consensus (ERIC) and Random Amplified Polymorphic DNA (RAPD) analyses revealed 21 and 18 distinct patterns of *K. pneumoniae* isolates with similarity >80%, respectively (Figs 1 and 2). The 21 ERIC genotypes were designated E1 to E21 while the RAPD genotypes were designated R1 to R18 and each of their variant subtypes were indicated by a letter suffix. Dendrogram analysis of ERIC genotyping showed three clusters (A–C): clusters A, B, and C contained 12/28, 9/28, and 7/28 of the MDR isolates, respectively. The isolates (18 and 21) and (28, 35, 51, and 56) showed high similarity which may suggest that those isolates constitute a clonal lineage (Fig. 1). On the other hand, the RAPD genotyping revealed different pattern with 6 clusters (A–F). The isolates (15 and 58), (20 and 21), (9 and 18), and (36 and 56) showed high similarity (Fig. 2). Based on Simpson's index of diversity, the discriminatory potential of different typing techniques used with *K. pneumoniae* isolates varied from 0.519 to 0.984 (Table 4). The high Simpson's index of diversity for the antibiotyping, virulence, RAPD, and ERIC typing indicates greater diversity. Kendall's tau-b correlation coefficient was calculated between RAPD and ERIC genotyping methods versus resistance patterns, virulence determinants, and capsule types of *K. pneumoniae*. Based on the statistical correlation tests (Table 5), the ERIC

Gene	Primer Sequence (5'-----3')	Amplicon size (bp)	Tm °C	Reference
<i>RmpA</i>	For: ACTGGGCTACCTCTGCTTCA Rev: CTGTCATGAGCCATCTTTCA	535	53	Siu, <i>et al.</i> ⁶²
<i>fimH-1</i>	For: GCCAACGTCTACGTTAACCTG Rev: ATATTTACGGTGCCTGAAAA	180	43	The current study
<i>mrkD</i>	For: CCACCAACTATTCCCTCGAA Rev: ATGGAACCCACATCGACATT	226	43	El Fertas-Aissani, <i>et al.</i> ⁴⁵
<i>arb</i>	For: TGGGGCAAAGAGGCGCTG GAG Rev: CAGCCAGCGACACGGATTCTC	636	51	The current study
<i>entB</i>	For: CTGCTGGGAAAAGCGATTGTC Rev: AAGGCGACTCAGGAGTGGCTT	385	49	The current study
<i>irP-1</i>	For: TGAATCGGGGTGTCTTATGC Rev: TCCCTCAATAAAGCCACGCT	238	49	El Fertas-Aissani, <i>et al.</i> ⁴⁵
<i>traT</i>	For: GGTGTGGTGCATGAGCACAG Rev: CACGGTTCAGCCATCCCTGAG	288	55	El Fertas-Aissani, <i>et al.</i> ⁴⁵
<i>AcrAB</i>	For: ATCAGCGGCCGATTGGTAAA Rev: CGGGTTCGGGAAAATAGCGCG	312	53	The current study
<i>tolC</i>	For: ATCAGCAACCCGATCTGCGT Rev: CCGGTGACTTGACGCAGTCTT	527	51	The current study
<i>mdtK</i>	For: GCGCTTAACTTCAGCTCA Rev: GATGATAAATCCACACCAGAA	453	43	The current study
<i>OmpK35</i>	For: CTCCAGCTCTAACCGTAGCG Rev: GGTCTGTACGTAGCCGATGG	241	51	The current study
<i>OmpK36</i>	For: GAAATTTATAACAAAGACGGC Rev: GACGTTACGTCTGATACTACG	305	43	The current study
<i>K1</i>	For: GGTGCTCTTACATCATTCG Rev: GCAATGGCCATTGCGTTAG	1283	47	Fang, <i>et al.</i> ⁶³
<i>K2</i>	For: GGATTATGACAGCCTCTCT Rev: CGACTTGGTCCCAACAGTTT	908	45	Fang, <i>et al.</i> ⁶³

Table 1. List of primers, expected amplicon size, and annealing temperatures.

genotyping significantly correlates with resistance patterns ($p < 0.01$) and virulence determinants ($p < 0.05$). On the other hand, the RAPD genotyping significantly correlates with resistance patterns ($p < 0.05$) but not with virulence determinants ($p > 0.05$). Both RAPD and ERIC genotyping methods have no correlation with the capsule types ($p > 0.05$).

Discussion

K. pneumoniae is the causative agent of several different healthcare-associated infections, such as bloodstream infections, wound infections, pneumonia, and meningitis. The extensive use of antimicrobials led to high incidence of resistance in *K. pneumoniae*²⁴. In our study, *K. pneumoniae* isolates showing multidrug resistance comprised 71.1% of total samples. Rates as high as 66.7% of MDR *K. pneumoniae* isolates were also detected in other studies²⁵. The high rates of antimicrobial resistance detected in our study can be attributed to the lack of strict policies that govern the use of antibiotics in Egypt³.

Antibiotic efflux pumps represent one of the most important antimicrobial resistance mechanisms used by *K. pneumoniae* clinical isolates^{26,27}. The increased efflux of the antimicrobial agent leads to the reduction of its intracellular concentration, which can enhance bacterial survival²⁸. The AcrAB efflux pump was more common than mdtK. The presence of the multidrug efflux pump system (AcrAB-TolC) was significantly correlated with the MDR pattern. On the other hand, five MDR isolates was missing either the AcrAB efflux pump or the TolC outer membrane protein or both.

Gram negative bacterial outer membranes are poorly permeable to both hydrophobic and hydrophilic molecules. Thus, most antimicrobial agents other than β -lactam must cross the membrane in order to reach their intracellular drug targets and so require the presence of porin to bypass the asymmetric bilayer of phospholipid and lipopolysaccharide membrane²⁹. Consequently, it has been reported that loss of porins ompK 35 and ompK 36 led to an increase in carbapenem, ciprofloxacin, and chloramphenicol resistance³⁰. Surprisingly, in our research, porin loss was not significantly correlated to the MDR pattern ($P > 0.05$). This could be attributed to the presence of point mutations, disruption in the protein coding sequence, or promoter region mutations³¹.

In the current study, about fifty percent of the total isolates showed resistance to both imipenem and ertapenem. In this context, there has been a significant increase in carbapenem resistance among *K. pneumoniae* isolates in Egypt during the last few years (from 13.9% to 44.4%)^{3,32,33}. *K. pneumoniae* isolates possess several mechanisms to evade the activity of carbapenems. These include AmpC production or ESBL production together with porin loss, carbapenemase production, and production of acquired Metallobetalactamase (MBL)³⁴.

Contrary to the New Delhi metallo- β -lactamase, which is a broad spectrum carbapenemase with ability to inactivate β -lactams except aztreonam³⁵, all carbapenem resistant isolates in our study were also resistant to aztreonem. This may be due to the development of a new antimicrobial resistance pattern in Egyptian hospitals. In all tested carbapenem-resistant isolates ($n = 18$), there was no simultaneous porin loss with AmpC or ESBL production. In another study³⁶, Szabó *et al.* showed that OmpD and OmpF in an ertapenem-resistant *E. coli* strain

Anti-biotype	Isolate No.	Antimicrobial resistance profile	Genes coding for porins and efflux pumps				
			OmpK35	OmpK36	MdtK	TolC	AcrAB
A1	1w	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AMK ^A -CN-TOB-CIP-NA-C	+	+	+	+	+
A2	3s	AMP-AMC-CAZ-CXM-AZM-TE-DOX ^A -NA ^A -SXT	-	-	-	+	+
A3	6w	AMP-AMC-TZP-FOX ^A -CAZ-CXM-AZM-CN-TOB-CIP-NA ^A -SXT-	+	+	-	+	+
A4	7s	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-CN-TOB	-	-	-	+	+
A5	8s	AMP-CAZ-CXM-AZM-TOB-TE-SXT-C	-	+	-	+	+
A6	9u	AMP-AMC-TZP-FOX-CAZ-CXM-IMP-ETP-AK-CN-TOB-CIP-NA	+	+	-	+	+
	21c		+	+	+	+	+
	26w		+	+	+	+	-
A7	10u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AK-TOB-CIP-NA-SXT-C ^A	+	+	+	+	+
A8	11u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AK-CN-TOB-TET-DOX-SXT-CIP-NA-C	-	+	+	+	+
	40b		+	-	-	+	+
	48b		-	+	-	+	+
A9	15u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AK-CN-TOB-SXT-CIP-NA-C	+	+	-	+	+
A10	18u	AMP-AMC-CAZ-CXM-AZM-TET-DO-SXT-C	-	+	-	+	+
A11	20s	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AK-CN-TOB-DO-SXT-CIP-NA-C	+	+	+	-	+
A12	28s	AMP-AMC-TZP-FOX ^A -CAZ-CXM-AZM-AK-ETP ^A -TET-DO ^A -SXT-CIP-NA	+	+	-	+	+
A13	33u	AMP-AMC-TZP-FOX-CAZ-CXM-IMP-ETP-AK-CN-TOB-CIP-NA	+	+	-	-	+
A14	35b	AMP-AMC-TZP-FOX-CAZ-CXM-IMP-ETP-AK-CN-TOB-DO-TET ^A -SXT-CIP-NA	+	+	+	+	+
A15	36u	AMP-AMC-TZP-CAZ-CXM-AZM-CN-TOB-TET-AK-DO-SXT ^A -CIP-NA	+	+	-	+	+
A16	41b	AMP-AMC-TZP-FOX-CAZ-CXM-IMP-ETP-AK-TOB-CIP ^A	+	-	-	+	+
A17	46w	AMP-AMC-CAZ-CXM-CN-TOB-TET-DOX ^A -CIP ^A -SXT	+	+	+	-	+
A18	47b	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-AK ^A -CN-TOB-TET-DO-CIP-NA-SXT ^A	+	+	+	+	+
A19	50u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-CN-DO-SXT-CIP ^A -NA	+	+	-	+	+
A20	51u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-CN-TOB-AK ^A -CIP-NA ^A -SXT	+	-	-	+	+
A21	53u	AMP-AMC-TZP ^A -CXM ^A -AZM ^A -CN-TOB-TET-DO-SXT-CIP-NA-C	+	+	-	-	+
A22	56u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-IMP-ETP-CN-TOB-AMK-TET-DO-CIP-NA-SXT	+	+	-	+	+
A23	57u	AMP-AMC-TZP-FOX-CAZ-CXM-CN-TOB ^A -TET-SXT-CIP-NA-C	+	+	-	+	+
A24	58u	AMP-AMC-TZP-FOX-CAZ-CXM-AZM-SXT-NA ^A -C	+	+	-	+	+

Table 2. Antimicrobial sensitivity patterns of multidrug resistant *Klebsiella pneumoniae* isolates and prevalence of genes coding for MDR efflux pumps (*AcrAB* & *MdtK*) and outer membrane porins (*OmpK35* & *OmpK36*). Abbreviations: u: urine, w- wound, s: sputum, c: CSF, b: blood. ^AIntermediate sensitivity. AMP: ampicillin; AMC: Amoxicillin/clavulanic acid; TZP: Piperacillin/tazobactam; CAZ: Ceftazidime; CXM: Cefuroxime; FOX: Cefoxitin; AZM: Azteronam; IMP: Imipenem; ETP: Ertapenem; AK: Amikacin; TET: Tetracycline; DO: Doxycycline; CN: Gentamicin; TOB: Tobramycin; CIP: Ciprofloxacin; NA: Nalidixic acid; SXT: Co-trimoxazole; C: Chloramphenicol.

were less permeable than those of a susceptible control strain. This suggested that the possession of these two porins could lead to higher resistance due to an associated pump system³⁶. This is relevant to our study given the fact that OmpF genes in *E. coli* are homologues to OmpK35 genes in *K. pneumoniae*²⁹.

Carbapenemase-producing enterobacteriaceae, such as *K. pneumoniae*, can cause deadly infections^{20,21}. Colistin was used to treat Gram-negative infections but was abandoned because of its toxicity. Recently, it has been revived again as a treatment for life-threatening infections caused by some resistant Gram-negative bacteria, such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*³⁷. Interestingly, all the tested *K. pneumoniae* isolates in this study were sensitive to colistin.

Both OmpK35 and OmpK36 play a role in *K. pneumoniae* virulence and infection. Deletion of *OmpK36* or *OmpK35/OmpK36* can lead to the reduction in virulence of highly virulent strains and can increase their susceptibility to neutrophil phagocytosis^{38,39}. In our investigation, both *OmpK35* and *OmpK36* porin-coding genes were simultaneously detected in all *K. pneumoniae* isolates recovered from wound and CSF samples. Their presence was variable though in sputum, blood, and urine samples. A direct correlation between efflux pumps and virulence of pathogenic bacteria was reported by Padilla *et al.*⁴⁰. Several genes essential for intracellular invasion and survival were downregulated in mutant strains lacking *acrAB-tolC* efflux pumps⁴¹.

Type 1 fimbriae are the most common adhesive organelles in enterobacteriaceae and can lead to urinary tract infections⁴². Type 3 fimbrial adhesin can mediate the binding of *K. pneumoniae* to endothelial cells and to epithelial cells of the respiratory and urinary tracts. MrkD protein is a crucial factor in binding bacteria to the collagen molecules of the mammalian cells⁴³. Many *K. pneumoniae* clinical isolates normally express both type 1 and type 3 fimbrial adhesins⁴⁴. In the current study, the two genes coding for these adhesive structures (Type 3 fimbrial adhesin and MrkD) were detected in all wound, blood, and CSF isolates and in about 80% of sputum and urine isolates. The plasmidic *traT* gene encodes an outer membrane protein involved in bacterial conjugation

Isolate code*	Capsule serotype	Virulence gene							Virulence genetic profile
		<i>rmpA</i>	<i>fimH-1</i>	<i>mrkD</i>	<i>traT</i>	<i>entB</i>	<i>Irp-1</i>	<i>IucC</i>	
1w	Non K1/K2	+	+	+	+	+	+	+	V1
3s	K1	-	+	+	+	-	+	-	V2
6w	K2	-	+	+	-	+	-	+	V3
7s	Non K1/K2	-	+	+	-	+	-	+	V4
8s	K1	-	+	+	+	+	+	-	V5
10u									
41b									
48b									
53u									
9u	K2	-	+	+	+	+	-	-	V6
11u	K1	+	+	+	+	+	-	+	V7
15u	Non K1/K2	-	+	+	-	+	-	-	V8
20s									
46w									
18u	Non K1/K2	-	+	+	+	+	-	-	V9
26w									
35b									
56u									
58u									
21c	Non K1/K2	+	+	+	+	+	-	-	V10
50u									
57u									
28s	Non K1/K2	-	+	-	+	+	-	+	V11
33u	Non K1/K2	-	-	+	+	-	-	-	V12
36u	Non K1/K2	-	-	+	+	+	-	+	V13
40b	K1	-	+	+	+	-	-	+	V14
47b	Non K1/K2	-	+	+	+	+	+	+	V15
51u	Non K1/K2	-	+	+	+	+	-	+	V16

Table 3. Distribution of virulence genetic profiles of *K. pneumoniae* isolates among capsule genotypes.

Abbreviations: u: urine, w- wound, s: sputum, c: CSF, b: blood. Non K1/K2 = Non typable as K1 or K2 capsule genotypes.

and blocks the complement-mediated cascade, and act as an invasin⁴⁵. We detected the *traT* gene in twenty two *K. pneumoniae* isolates (78.5%). The prevalence of *traT* gene in our isolates was relatively high as it was frequently associated with the K1 capsule serotype.

Most enterobacteriaceae strains contain genes encoding iron uptake systems, such as enterochelin or aerobactin⁴⁶. These siderophores have dual roles as they can also inhibit T cell proliferation in addition to their role in enhancing iron uptake⁴⁷. The iron siderophores aerobactin synthase gene (*IucC*), enterobactin biosynthesis gene (*entB*), and yersinibactin biosynthesis gene (*Irp-1*) were detected in 32.14%, 78.5%, and 10.7% of MDR *K. pneumoniae* isolates, respectively. Highly pathogenic Yersinia strains have high-pathogenicity island (HPI) that contain the gene *Irp-1*. This HPI is also prevalent in *Klebsiella* and other enterobacteria⁴⁸, such as *E. coli*, *K. oxytoca*, *K. pneumoniae*, *Citrobacter* species, and *Enterobacter* species⁴⁶.

The capsular serotypes K1 and K2 are associated with the predominant virulent strains of *K. pneumoniae*⁴⁹. Feizabadi *et al.* has shown that K1 and K2 serotypes represented 11.2% and 14.6%, respectively, of the total *K. pneumoniae* isolates⁵⁰. In our study, K1 and K2 serotypes represented 28.5% and 7.14% of the MDR *K. pneumoniae* isolates.

Molecular typing is a potent tool for the study of nosocomial infections⁵¹. RAPD is a widely used genotyping tool for *K. pneumoniae* strains with ESBLs production (Gori *et al.*, 1996). Out of a total of 28 MDR *K. pneumoniae* isolates in the current investigation, ERIC-PCR revealed 21 and RAPD-PCR revealed 18 distinct patterns of *K. pneumoniae* isolates. This may be attributed to the genetic variation in pathogenic these *K. pneumoniae* strains. Our data confirms the observations of Lai *et al.*⁵² that pathogenic *K. pneumoniae* is highly heterogeneous, due to differences in nucleotide sequences. The large number of serotypes in this species could also explain this genetic diversity highlighted by the RAPD-PCR genotypic analysis⁵³.

Correlations between RAPD-PCR genotyping and antibiotic resistance patterns of *K. pneumoniae* were observed by Ashayeri-Panah *et al.*⁵⁴ and Espinar *et al.*⁵⁵. In the current study, both RAPD-PCR and ERIC-PCR genotypic analyses revealed correlations with resistance patterns of *K. pneumoniae*. The highest correlation coefficients were observed with ERIC genotyping, indicating that the latter may be more valuable in prediction of resistance patterns of *K. pneumoniae* as compared to the RAPD-PCR genotyping method. Moreover, ERIC, but not RAPD-PCR, revealed statistically significant correlations with virulence determinants of *K. pneumoniae*.




Figure 1. Dendrogram generated with Dice coefficient and the UPGMA clustering method, showing the genetic similarity among *K. pneumoniae* isolates by Enterobacterial Repetitive Intergenic Consensus (ERIC) genotyping.

Finally, both RAPD-PCR and ERIC-PCR showed no statistically significant correlation with the detected capsule types of *K. pneumoniae* isolates. Results included in this study can help up better predict MDR *Klebsiella pneumoniae* outbreaks associated with specific genotyping patterns in the future.

Materials and Methods

Bacterial strains. Thirty six *K. pneumoniae* clinical isolates were recovered from patients at Kasr El Aini Hospitals, Cairo, Egypt. Approvals from the institutional review board of the hospitals and the Research Ethics committee of the October University for Modern Sciences and Arts, Giza, Egypt were obtained prior to conducting the study. All methods were performed in accordance with the required guidelines and regulations.

For experiments involving human samples, informed consent was obtained from all subjects. Strains were isolated from sputum, urine, blood, wound, and cerebrospinal fluid (CSF) specimens. Specimens were collected in the period from August 2015 through December 2015. Isolates were identified by conventional and biochemical tests as described previously⁵⁶ and then were stored at -20°C in brain heart infusion broth with 15% v/v glycerol.

Antimicrobial susceptibility. Antibiotic susceptibility testing of *Klebsiella sp.*, was performed according to the Kirby-Bauer disk diffusion method⁵⁷. The antimicrobial sensitivity assays to nineteen antibacterial drugs were done using commercially available antibiotic discs (OXOID, UK) including Ampicillin (AMP, 10 μg), Amoxicillin/Clavulanic acid (AMC, 20/10 μg), Piperacillin/Tazobactam (TZP, 110/10 μg), Cefoxitin (FOX, 30 μg), Ceftazidime (CAZ, 30 μg), Cefuroxime (CXM, 30 μg), Aztreonam (ATM, 30 μg), Ertapenem (ETP, 10 μg), Impinem (IMP, 10 μg), Gentamicin (CN, 10 μg), Tobramycin (TOB, 10 μg), Amikacin (AK, 30 μg), Tetracycline (TE, 30 μg), Doxycycline (DO, 30 μg), Ciprofloxacin (CIP, 5 μg), Nalidixic acid (NA, 30 g), Co-trimoxazole (SXT, 30 μg), Colistin (CT, 10 μg) and Chloramphenicol (C, 30 μg). For all tested antimicrobials except colistin (10 μg), the plates were then incubated at 37°C for 24 hours, the diameters of the inhibition zones were measured in millimeter and interpretation of results was done according to CLSI standards⁵⁷. For Colistin, breakpoints were used for interpretation⁵⁸. Multidrug resistant (MDR) isolates were selected according to their non-susceptibility to at least one agent in three or more antimicrobial categories⁵⁹.

Detection of multidrug resistance and virulence determinants using PCR. *DNA extraction.* Genomic DNA was extracted from overnight culture using ZYMO Quick-gDNA™ MiniPrep (ZYMO Research, CA, USA). Concentration of the DNA extract and purity was determined by measuring absorbance at wavelengths 260 and 280 nm. The integrity of genomic DNA was tested by resolving DNA extracts on a 0.8% w/v agarose gel by electrophoresis. These crude DNA extracts were frozen at -20°C .




Figure 2. Dendrogram generated with Dice coefficient and the UPGMA clustering method, showing the genetic similarity among *K. pneumoniae* isolates by Random Amplified Polymorphic DNA (RAPD) genotyping.

Primers used for amplification are listed in Table 1 and were prepared by Invitrogen® (Thermo Fisher scientific Inc., MA, USA). Primers were designed using the complete genome sequence of *K. pneumoniae* MGH 78578 (accession no. CP000647) and the internet based software Basic Local Alignment Tool (BLAST) in NCBI and Multiple sequence alignment using the CLUSTAL Omega in EMBL-EBI.

PCR detection of multidrug resistance genes. Isolates that showed multidrug resistance phenotypes were tested for genes coding for the multidrug efflux pump system *AcrAB-TolC* and *MdtK*, in addition to porin coding genes (*OmpK35* and *OmpK36*). The amplifications of these genes were performed in cycles with initial denaturing at 94 °C for 5 min followed by 35 cycles, each cycle consisting of 30 seconds at 94 °C for denaturation, 30 seconds for primer annealing (Table 1), and 1.5 min at 72 °C for elongation. After these cycles, the final elongation step was carried out at 72 °C for 10 min⁴⁵.

PCR detection of virulence-associated genes. PCR was used to amplify the virulence-associated genes. These genes include those encoding for regulators of mucoid phenotype A (*rmpA*), type 1 and type 3 adhesins (*fimH-1*, *mrkD*), aerobactin (iron siderophore) synthase (*IucC*), bacteriocin biosynthesis [enterobactin (*entB*), and yersiniabactin (*irP-1*)], and serum resistance-associated outer membrane lipoprotein (*traT*). Measurements of the prevalence of capsule serotypes K1 and K2 were also included.

The PCR conditions were similar to those used for detection of multidrug resistance genes with annealing temperatures included in Table 1.

Molecular typing of *Klebsiella pneumoniae* isolates using Random Amplified Polymorphic DNA (RAPD) and Enterobacterial Repetitive Intergenic Consensus (ERIC) methods. Typing by

Isolate code	Antibiogram	Virulence gene pattern typing	Capsule serotyping	ERIC typing	RAPD typing
1w	A1	V1	Non K1/K2	E1	R1
3s	A2	V2	K1	E2	R2
6w	A3	V3	K2	E3	R3a
7s	A4	V4	Non K1/K2	E4	R4
8s	A5	V5	K1	E5	R5
9u	A6	V6	K2	E6	R6a
10u	A7	V5	K1	E7a	R7
11u	A8	V7	K1	E8a	R8a
15u	A9	V8	Non K1/K2	E20	R9
18u	A10	V9	Non K1/K2	E9a	R6a
20s	A11	V8	Non K1/K2	E10	R10
21c	A6	V10	Non K1/K2	E9a	R10
26w	A6	V9	Non K1/K2	E9b	R11
28s	A12	V11	Non K1/K2	E13	R3b
33u	A13	V12	Non K1/K2	E21	R12
35b	A14	V9	Non K1/K2	E13	R13
36u	A15	V13	Non K1/K2	E19	R3d
40b	A8	V14	Non K1/K2	E11	R14
41b	A16	V5	K1	E14	R15a
46w	A17	V8	Non K1/K2	E18	R18
47b	A18	V13	Non K1/K2	E7b	R17
48b	A8	V5	K1	E15	R15b
50u	A19	V10	Non K1/K2	E12	R16
51u	A20	V15	Non K1/K2	E13	R3c
53u	A21	V5	K1	E17	R6b
56u	A22	V9	Non K1/K2	E13	R3d
57u	A23	V10	Non K1/K2	E8b	R8b
58u	A24	V9	Non K1/K2	E16	R9
Simpsons index of diversity	0.984	0.925	0.519	0.969	0.955

Table 4. Discriminatory potential of typing techniques for *K. pneumoniae* isolates.

Genotyping method	Resistance pattern	Virulence determinant	Capsule type
RAPD	0.306' ($p < 0.05$)	0.268 ($p = 0.053$)	0.106 ($p = 0.497$)
ERIC	0.520' ($p < 0.01$)	0.352' ($p < 0.05$)	0.210 ($p = 0.181$)

Table 5. Kendall's tau-b correlation coefficient of Random Amplified Polymorphic DNA (RAPD) and Enterobacterial Repetitive Intergenic Consensus (ERIC) genotyping methods versus resistance patterns, virulence determinants, and capsule types of *K. pneumoniae* isolates. *Correlation is significant at $p < 0.05$ (two-tailed).

randomly amplified polymorphic DNA (RAPD) analysis was performed according to the protocol published by Deschaght *et al.*⁶⁰ using the primer RAPD4 (5'-AAGACGCCGT-3'). Briefly, two microliters of the DNA template were added to 12.5 μ L multiplex mastermix (MyTaqTM HM Mix, Bioline[®], MA, USA), 1 μ L primer (10 pmol), and 9.5 μ L H₂O. PCR cycles of initial incubation at 94 °C for 15 min followed by cycling for 40 times at 94 °C for 1 min, 37 °C for 1 min, and a final elongation at 72 °C for 2 min was performed.

ERIC typing was carried out using the primer ERIC2 (5'-AAGTAAGTGACTGGGGTGAGCG-3') using a similar PCR program to that of the RAPD method except for an extension time of 8 min⁵⁹.

RAPD and ERIC fragments were visualized by 1.5% w/v agarose gel electrophoresis and results were analyzed using GelCompar II software (Version 6.6.11, Applied Maths, Kortrijk, Belgium). The patterns were normalized with bands of the marker and bands that were consistently present in all patterns. Computer-assisted analyses implemented in this study were performed according to the manufacturer's instructions.

Comparing different typing methods and calculation of discriminatory index. Simpsons index of diversity [discriminatory index (D)], based on the probability that two unrelated isolate samples from the test population are located in different typing groups, was calculated according to the following equation:

$$D = 1 - \frac{1}{N - 1} \cdot \sum_{j=1}^s nj(nj - 1)$$

where N is the total number of isolates in the sample population, s is the total number of types described, and nj is the number of strains belonging to the jth type. Simpsons index of diversity ranges from 0.0 to 1.0, where 1.0 indicates that a typing method is able to distinguish each member of a population from all other members of that population and, conversely, 0.0 indicates that all members of a strain population are of an identical type⁶¹.

Statistical analysis. All statistical analyses were performed using SPSS, version 18.0 (SPSS Inc., NY, USA). Chi-square tests were used to compare categorical measures between groups (Fisher's exact test where appropriate). Statistical correlation tests, including Kendall's tau-b nonparametric correlation coefficients, were determined at the two-tailed significance level for correlation of genotyping methods with virulence determinants, antimicrobial resistance, and capsule types. Data output of correlation analyses with p values less than 0.05 were considered statistically significant.

References

1. Brisse, S. & Verhoef, J. Phylogenetic diversity of *Klebsiella pneumoniae* and *Klebsiella oxytoca* clinical isolates revealed by randomly amplified polymorphic DNA, gyrA and parC genes sequencing and automated ribotyping. *Int J Syst Evol Microbiol* **51**, 915–924, doi: 10.1099/00207713-51-3-915 (2001).
2. Lin, W. H. *et al.* Clinical and microbiological characteristics of *Klebsiella pneumoniae* isolates causing community-acquired urinary tract infections. *Infection* **38**, 459–464, doi: 10.1007/s15010-010-0049-5 (2010).
3. Daef, E. A. & Elsherbiny, N. M. Clinical and Microbiological Profile of Nosocomial Infections in Adult Intensive Care Units at Assiut University Hospitals, Egypt. *Journal of American Science* **8**, 1239–1250 (2012).
4. Abdel-Wahab, F., Ghoneim, M., Khashaba, M., El-Gilany, A. H. & Abdel-Hady, D. Nosocomial infection surveillance in an Egyptian neonatal intensive care unit. *J Hosp Infect* **83**, 196–199, doi: 10.1016/j.jhin.2012.10.017 (2013).
5. Fuursted, K. *et al.* Virulence of a *Klebsiella pneumoniae* strain carrying the New Delhi metallo-beta-lactamase-1 (NDM-1). *Microbes Infect* **14**, 155–158, doi: 10.1016/j.micinf.2011.08.015 (2012).
6. Lawlor, M. S., O'Connor, C. & Miller, V. L. Yersiniabactin Is a Virulence Factor for *Klebsiella pneumoniae* during Pulmonary Infection. *Infection and Immunity* **75**, 1463–1472, doi: 10.1128/IAI.00372-06 (2007).
7. Wu, C.-C. *et al.* IscR Regulation of Capsular Polysaccharide Biosynthesis and Iron-Acquisition Systems in *Klebsiella pneumoniae* CG43. *PLoS One* **9**, e107812, doi: 10.1371/journal.pone.0107812 (2014).
8. Tanwar, J., Das, S., Fatima, Z. & Hameed, S. Multidrug Resistance: An Emerging Crisis. *Interdisciplinary Perspectives on Infectious Diseases* **2014**, 7, doi: 10.1155/2014/541340 (2014).
9. Munoz-Price, L. S. & Quinn, J. P. The Spread of *Klebsiella pneumoniae* Carbapenemases: A Tale of Strains, Plasmids, and Transposons. *Clinical Infectious Diseases* **49**, 1739–1741, doi: 10.1086/648078 (2009).
10. Falagas, M. E. & Karageorgopoulos, D. E. Extended-spectrum beta-lactamase-producing organisms. *J Hosp Infect* **73**, 345–354, doi: 10.1016/j.jhin.2009.02.021 (2009).
11. Miro, E. *et al.* Spread of plasmids containing the bla(VIM-1) and bla(CTX-M) genes and the qnr determinant in *Enterobacter cloacae*, *Klebsiella pneumoniae* and *Klebsiella oxytoca* isolates. *J Antimicrob Chemother* **65**, 661–665, doi: 10.1093/jac/dkp504 (2010).
12. Meletis, G., Exindari, M., Vavatsi, N., Sofianou, D. & Diza, E. Mechanisms responsible for the emergence of carbapenem resistance in *Pseudomonas aeruginosa*. *Hippokratia* **16**, 303–307 (2012).
13. Du, D. *et al.* Structure of the AcrAB-TolC multidrug efflux pump. *Nature* **509**, 512–515, doi: 10.1038/nature13205 (2014).
14. Okusu, H., Ma, D. & Nikaido, H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of *Escherichia coli* multiple-antibiotic-resistance (Mar) mutants. *Journal of Bacteriology* **178**, 306–308 (1996).
15. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. *Biochemical and Biophysical Research Communications* **453**, 254–267, doi: http://dx.doi.org/10.1016/j.bbrc.2014.05.090 (2014).
16. Shi, W. *et al.* Carbapenem and cefoxitin resistance of *Klebsiella pneumoniae* strains associated with porin OmpK36 loss and DHA-1 beta-lactamase production. *Braz J Microbiol* **44**, 435–442, doi: 10.1590/s1517-83822013000200015 (2013).
17. Vardakas, K. Z., Tansarli, G. S., Rafailidis, P. I. & Falagas, M. E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy* **67**, 2793–2803, doi: 10.1093/jac/dks301 (2012).
18. CDC. Vital Signs: Carbapenem-Resistant Enterobacteriaceae. 165–170 (Center for Disease Control and prevention (CDC), 2013).
19. Ben-David, D. *et al.* Outcome of carbapenem resistant *Klebsiella pneumoniae* bloodstream infections. *Clinical Microbiology and Infection* **18**, 54–60, doi: 10.1111/j.1469-0691.2011.03478.x (2012).
20. Patel, G. *et al.* Outcomes of Carbapenem-Resistant *Klebsiella pneumoniae* Infection and the Impact of Antimicrobial and Adjunctive Therapies. *Infection Control and Hospital Epidemiology* **29**, 1099–1106, doi: 10.1086/592412 (2008).
21. Chang, H.-J. *et al.* Risk factors and outcomes of carbapenem-nonsusceptible *Escherichia coli* bacteremia: A matched case-control study. *Journal of Microbiology, Immunology and Infection* **44**, 125–130, doi: 10.1016/j.jmii.2010.06.001 (2011).
22. Falagas, M. E. & Kopterides, P. Old antibiotics for infections in critically ill patients. *Current Opinion in Critical Care* **13**, 592–597, doi: 10.1097/MCC.0b013e32827851d7 (2007).
23. Falagas, M. E., Kasiakou, S. K. & Saravolatz, L. D. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. *Clinical Infectious Diseases* **40**, 1333–1341, doi: 10.1086/429323 (2005).
24. Cao, X. *et al.* Molecular characterization of clinical multidrug-resistant *Klebsiella pneumoniae* isolates. *Annals of Clinical Microbiology and Antimicrobials* **13**, 16–16, doi: 10.1186/1476-0711-13-16 (2014).
25. Paneru, T. P. Surveillance of *Klebsiella pneumoniae* and antibiotic resistance a retrospective and comparative study through a period in Nepal. *Danish journal of medical and biology sciences*, 29–36 (2015).
26. Peleg, A. Y. & Hooper, D. C. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med* **362**, 1804–1813, doi: 10.1056/NEJMra0904124 (2010).
27. Zavascki, A. P., Carvalhaes, C. G., Picao, R. C. & Gales, A. C. Multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: resistance mechanisms and implications for therapy. *Expert Rev Anti Infect Ther* **8**, 71–93, doi: 10.1586/eri.09.108 (2010).
28. Piddock, L. J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbiol Rev* **19**, 382–402, doi: 10.1128/cmr.19.2.382-402.2006 (2006).
29. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol Mol Biol Rev* **67**, 593–656 (2003).
30. Kaczmarek, F. M., Dib-Hajj, F., Shang, W. & Gootz, T. D. High-Level Carbapenem Resistance in a *Klebsiella pneumoniae* Clinical Isolate Is Due to the Combination of bla(CT-1) beta-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-

- Regulation of the Phosphate Transport Porin PhoE. *Antimicrobial Agents and Chemotherapy* **50**, 3396–3406, doi: 10.1128/AAC.00285-06 (2006).
31. Doumith, M., Ellington, M. J., Livermore, D. M. & Woodford, N. Molecular mechanisms disrupting porin expression in ertapenem-resistant *Klebsiella* and *Enterobacter* spp. clinical isolates from the UK. *J Antimicrob Chemother* **63**, 659–667, doi: 10.1093/jac/dkp029 (2009).
 32. Ashour, H. M. & El-Sharif, A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. *J Transl Med* **7**, 14, doi: 10.1186/1479-5876-7-14 (2009).
 33. Metwally, L., Gomaa, N., Attallah, M. & Kamel, N. High prevalence of *Klebsiella pneumoniae* carbapenemase-mediated resistance in *K. pneumoniae* isolates from Egypt. *East Mediterr Health J* **19**, 947–952 (2013).
 34. Pfeifer, Y., Cullik, A. & Witte, W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. *International Journal of Medical Microbiology* **300**, 371–379, doi: http://dx.doi.org/10.1016/j.ijmm.2010.04.005 (2010).
 35. Shakil, S. *et al.* New Delhi metallo-beta-lactamase (NDM-1): an update. *J Chemother* **23**, 263–265, doi: 10.1179/joc.2011.23.5.263 (2011).
 36. Szabó, D. *et al.* Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in *Enterobacter cloacae*. *Antimicrobial Agents and Chemotherapy* **50**, 2833–2835, doi: 10.1128/AAC.01591-05 (2006).
 37. Karabinis, A. *et al.* Colistin for *Klebsiella pneumoniae*—Associated Sepsis. *Clinical Infectious Diseases* **38**, e7–e9, doi: 10.1086/380461 (2004).
 38. Chen, J. H. *et al.* Contribution of outer membrane protein K36 to antimicrobial resistance and virulence in *Klebsiella pneumoniae*. *J Antimicrob Chemother* **65**, 986–990, doi: 10.1093/jac/dkq056 (2010).
 39. Tsai, Y.-K. *et al.* *Klebsiella pneumoniae* Outer Membrane Porins OmpK35 and OmpK36 Play Roles in both Antimicrobial Resistance and Virulence. *Antimicrobial Agents and Chemotherapy* **55**, 1485–1493, doi: 10.1128/AAC.01275-10 (2011).
 40. Padilla, E. *et al.* *Klebsiella pneumoniae* AcrAB efflux pump contributes to antimicrobial resistance and virulence. *Antimicrob Agents Chemother* **54**, 177–183, doi: 10.1128/aac.00715-09 (2010).
 41. Webber, M. A., Randall, L. P., Cooles, S., Woodward, M. J. & Piddock, L. J. V. Triclosan resistance in *Salmonella enterica* serovar Typhimurium. *Journal of Antimicrobial Chemotherapy* **62**, 83–91, doi: 10.1093/jac/dkn137 (2008).
 42. Struve, C., Bojer, M. & Krogfelt, K. A. Characterization of *Klebsiella pneumoniae* type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence. *Infect Immun* **76**, 4055–4065, doi: 10.1128/iai.00494-08 (2008).
 43. Langstraat, J., Bohse, M. & Clegg, S. Type 3 fimbrial shaft (MrkA) of *Klebsiella pneumoniae*, but not the fimbrial adhesin (MrkD), facilitates biofilm formation. *Infect Immun* **69**, 5805–5812 (2001).
 44. Sahly, H. *et al.* Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **52**, 3029–3034, doi: 10.1128/aac.00010-08 (2008).
 45. El Fertas-Aissani, R., Messai, Y., Alouache, S. & Bakour, R. Virulence profiles and antibiotic susceptibility patterns of *Klebsiella pneumoniae* strains isolated from different clinical specimens. *Pathol Biol (Paris)* **61**, 209–216, doi: 10.1016/j.patbio.2012.10.004 (2013).
 46. Schubert, S., Cuenca, S., Fischer, D. & Heesemann, J. High-pathogenicity island of *Yersinia pestis* in enterobacteriaceae isolated from blood cultures and urine samples: prevalence and functional expression. *J Infect Dis* **182**, 1268–1271, doi: 10.1086/315831 (2000).
 47. Autenrieth, I., Hantke, K. & Heesemann, J. Immunosuppression of the host and delivery of iron to the pathogen: a possible dual role of siderophores in the pathogenesis of microbial infections? *Med Microbiol Immunol* **180**, 135–141 (1991).
 48. Carniel, E. The *Yersinia* high-pathogenicity island: an iron-uptake island. *Microbes Infect* **3**, 561–569 (2001).
 49. Turton, J. F., Baklan, H., Siu, L. K., Kaufmann, M. E. & Pitt, T. L. Evaluation of a multiplex PCR for detection of serotypes K1, K2 and K5 in *Klebsiella* sp. and comparison of isolates within these serotypes. *FEMS Microbiol Lett* **284**, 247–252, doi: 10.1111/j.1574-6968.2008.01208.x (2008).
 50. Feizabadi, M. M., Raji, N. & Delfani, S. Identification of *Klebsiella pneumoniae* K1 and K2 Capsular Types by PCR and Quellung Test. *Jundishapur J Microbiol* **6**, e7585, doi: 10.5812/jjm.7585 (2013).
 51. Boccia, S. *et al.* Genotypic analysis by 27A DNA fingerprinting of *Candida albicans* strains isolated during an outbreak in a neonatal intensive care unit. *Infect Control Hosp Epidemiol* **23**, 281–284, doi: 10.1086/502052 (2002).
 52. Lai, Y. C., Yang, S. L., Peng, H. L. & Chang, H. Y. Identification of genes present specifically in a virulent strain of *Klebsiella pneumoniae*. *Infect Immun* **68**, 7149–7151 (2000).
 53. de Souza Lopes, A. C., Falcão Rodrigues, J. & Antônio de Moraes Júnior, M. Molecular typing of *Klebsiella pneumoniae* isolates from public hospitals in Recife, Brazil. *Microbiological Research* **160**, 37–46, doi: http://dx.doi.org/10.1016/j.micres.2004.09.007 (2005).
 54. Ashayeri-Panah, M., Feizabadi, M. M. & Eftekhari, F. Correlation of Multi-drug Resistance, Integron and blaESBL Gene Carriage With Genetic Fingerprints of Extended-Spectrum β -Lactamase Producing *Klebsiella pneumoniae*. *Jundishapur Journal of Microbiology* **7**, e8747, doi: 10.5812/jjm.8747 (2014).
 55. Espinar, M. J. *et al.* Urinary Tract Infections in Kidney Transplant Patients Due to *Escherichia coli* and *Klebsiella pneumoniae* -Producing Extended-Spectrum β -Lactamases: Risk Factors and Molecular Epidemiology. *PLoS ONE* **10**, e0134737, doi: 10.1371/journal.pone.0134737 (2015).
 56. Collee, J. In *Mackie & McCartney Practical Medical Microbiology* (ed Collee, J. G., Fraser, A. G., Marimon, B. P., Simmons, A.) (Elsevier, 2007).
 57. CLSI. (Clinical and Laboratory Standards Institute, PA, USA, 2014).
 58. EUCAST. 1–91 (European committee on antimicrobial susceptibility testing, 2016).
 59. Cabral, A. B., Melo Rde, C., Maciel, M. A. & Lopes, A. C. Multidrug resistance genes, including bla(KPC) and bla(CTX)-M-2, among *Klebsiella pneumoniae* isolated in Recife, Brazil. *Rev Soc Bras Med Trop* **45**, 572–578 (2012).
 60. Deschaght, P. *et al.* Rapid genotyping of *Achromobacter xylosoxidans*, *Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* isolates using melting curve analysis of RAPD-generated DNA fragments (McRAPD). *Research in Microbiology* **162**, 386–392, doi: http://dx.doi.org/10.1016/j.resmic.2011.02.002 (2011).
 61. de la Puente-Redondo, V. A., del Blanco, N. G., Gutierrez-Martin, C. B., Garcia-Pena, F. J. & Rodriguez Ferri, E. F. Comparison of different PCR approaches for typing of *Francisella tularensis* strains. *J Clin Microbiol* **38**, 1016–1022 (2000).
 62. Siu, L. K. *et al.* Molecular Typing and Virulence Analysis of Serotype K1 *Klebsiella pneumoniae* Strains Isolated from Liver Abscess Patients and Stool Samples from Noninfectious Subjects in Hong Kong, Singapore, and Taiwan. *Journal of Clinical Microbiology* **49**, 3761–3765, doi: 10.1128/JCM.00977-11 (2011).
 63. Fang, C. T. *et al.* *Klebsiella pneumoniae* genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. *Clin Infect Dis* **45**, 284–293, doi: 10.1086/519262 (2007).

Author Contributions

Dr. Reham Wasfi, Dr. Walid F. Elkhatib, and Dr. Hossam M. Ashour contributed to the design of the study, performance of experiments, analysis of the results, and writing of the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wasfi, R. *et al.* Molecular typing and virulence analysis of multidrug resistant *Klebsiella pneumoniae* clinical isolates recovered from Egyptian hospitals. *Sci. Rep.* **6**, 38929; doi: 10.1038/srep38929 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016